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contaminated and recipients developed infections. An 
unwritten change to autoclave operation, communicated 
orally between operators, resulted in dextrose intravenous 
solutions that were not uniformly sterile. The Clothier 
inquiry, which examined the causes and contributing 
factors, identified several violations of what we now 
consider basic good manufacturing practice (GMP). 
The chain of events that compromised the safety of the 
drug product included inadequate maintenance, inadequate 
understanding of autoclave operation, and regular 
deviations from the written production instructions (often 
as an attempt to compensate for equipment malfunction). 
Together, these factors resulted in a sterilization cycle that 
did not assure that all vials in the autoclave were sterilized; 
thus, some doses were safe, while others led to sepsis in 
patients who received them. This incident helped to define 
sterility assurance in an operational way. Processes and 
requirements for equipment validation were created, and 
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Tragic incident
It is a truism that it takes a disaster to happen for people, 
and especially regulators, to wake up and review the 
accepted way of doing things. So, too, with the issue of 
drug safety and drug quality.[1]
The 1972 Devonport, UK, incident resulted in at least five 
deaths when drug products designed to be sterile became 
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legal right of inspection was explicitly given to the agency. 
Validation was developed as a means of documenting 
systematic evaluation of the sterilization cycle — building 
in a safety factor — and identifying the critical parameters 
that need to be controlled to assure process performance. 
The concept that quality must be designed into the process 
and cannot be achieved only by testing remains a central 
tenet of current good manufacturing practice (cGMP). 
In other words, how you make something helps to define 
its level of quality. Preventing errors is more effective 
than finding rejects because it is not possible to detect all   
rejects.[2] The current requirement for ‘documented 
evidence’ may be driven by this event of Devenport.
GOOD MANUFACTURING PRACTICES
GMP is that part of quality assurance which ensures that 
products are consistently produced and controlled to the 
quality standards appropriate to their intended use. GMP 
is aimed primarily at diminishing the risk inherent in any 
pharmaceutical production. Such risks are essentially of two 
types: cross-contamination (in particular, with unexpected 
contaminants) and mix-ups (for example, false labeling).[3]
Worldwide, there are different official regulatory statements 
and guidelines, both national and international, for GMP 
for pharmaceutical (or ‘drug’ or ‘medicinal’) products. 
They may be regulations (as in the US, Japan, or Korea), 
directives (as in the EU), guides (as in the UK), codes (as 
in Australia), or a WHO code (as in many Southeast Asia 
Countries). Among them, the following stand out as the 
most influential and most frequently referenced:
•  The US Current Good Manufacturing Practices   
for Finished Pharmaceuticals regulations (the US 
cGMPs).[4]
•  The Guide to Good Manufacturing Practice for 
Medicinal Products of the European Union (the EC 
GMP Guide).[5]
•  The ICH Q7 Good Manufacturing Practice Guide for 
Active Pharmaceutical Ingredients.[6] 
•  The World Health Organization (WHO) good 
manufacturing practices.[7]
The other guidelines and regulations referred by the 
pharmaceutical manufacturers are as under:
•  Schedule M ‘Good Manufacturing Practices and 
Requirements of Premises, Plant and Equipment for 
Pharmaceutical Products,’ The Drugs and Cosmetics 
Act and Rules, India.[8]
•  PIC/S Guide to Good Manufacturing Practice for 
Medicinal Products.[9]
•  Center for Drug Evaluation and Research (CDER): 
Manufacturing, Processing, or Holding Active 
Pharmaceutical Ingredients.[10]
DOCUMENTATION
Documentation is the key to GMP compliance and ensures 
traceability of all development, manufacturing, and testing 
activities. Documentation provides the route for auditors to 
assess the overall quality of operations within a company 
and the final product.
The 10 golden rules of GMP[11]
Table 1 describes the 10 golden rules of GMP. Rule No. 
3 and 5 describe the importance of documentation and 
records. 
Basics[12]
•  The management of each operational site is required 
to define responsibility for origination, distribution, 
maintenance, change control, and archiving of all GMP 
documentation and records within that department or 
unit.
•  Document owners are required to ensure that all aspects 
of documentation and records management specified 
in form of standard operating procedures (SOPs).  
•  All associates have the responsibility of ensuring that all 
GMP activities are performed according to the official 
SOPs; any deviations in procedure are reported to their 
supervisor and are adequately documented.
•  The local quality assurance unit has the responsibility 
of ensuring via organizational measures and auditing 
that GMP documentation and records systems used 
within the operational unit are complete and comply 
with the relevant GMP requirements, and also that the 
requirements of the SOPs are followed.
•  Requirements for specific documents or record, 
including ownership, content, authorization, and change 
Table 1: The 10 golden rules of GMP
Number The golden rule 
1 Get the facility design right from the start
2 Validate processes
3 Write good procedures and follow them
4 Identify who does what
5 Keep good records
6 Train and develop staff
7 Practice good hygiene
8 Maintain facilities and equipment
9 Build quality into the whole product lifecycle
10 Perform regular audits
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control procedures, has to be described or cross-
referenced in the quality modules which relate to the 
subject of the document.
General requirements[13] 
•  Good documentation constitutes an essential part of 
the quality assurance system. Clearly written procedures 
prevent errors resulting from spoken communication, 
and clear documentation permits tracing of activities 
performed.
•  Documents must be designed, prepared, reviewed, and 
distributed with care. 
•  Documents must be approved, signed, and dated by 
the appropriate competent and authorized persons.
•  Documents must have unambiguous contents. The title, 
nature, and purpose should be clearly stated. They must 
be laid out in an orderly fashion and be easy to check. 
Reproduced documents must be clear and legible.
•  Documents must be regularly reviewed and kept up-to-
date. When a document has been revised, systems must 
be operated to prevent inadvertent use of superseded 
documents (e.g., only current documentation should be 
available for use).
•  Documents must not be handwritten; however, where 
documents require the entry of data, these entries may 
be made in clear legible handwriting using a suitable 
indelible medium (i.e., not a pencil). Sufficient space 
must be provided for such entries.
•  Any correction made to a document or record must 
be signed or initialed and dated; the correction must 
permit the reading of the original information. Where 
appropriate, the reason for the correction must be 
recorded.
•  Record must be kept at the time each action is taken and 
in such a way that all activities concerning the conduct 
of preclinical studies, clinical trials, and the manufacture 
and control of products are traceable.
•  Storage of critical records must at secure place, with 
access limited to authorized persons. The storage 
location must ensure adequate protection from loss, 
destruction, or falsification, and from damage due to 
fire, water, etc.
•  Records which are critical to regulatory compliance or to 
support essential business activities must be duplicated 
on paper, microfilm, or electronically, and stored in a 
separate, secure location in a separate building from the 
originals.
•  Date may be recorded by electromagnetic or 
photographic means, but detailed procedures relating 
to whatever system is adopted must be available. 
Accuracy of the record should be checked as per the 
defined procedure. If documentation is handled by 
electronic data processing methods, only authorized 
persons should be able to enter or modify data in the 
computer, access must be restricted by passwords 
or other means, and entry of critical data must be 
independently checked.
•  It is particularly important that during the period of 
retention, the data can be rendered legible within an 
appropriate period of time.
•  If data is modified, it must be traceable.
There are various types of procedures that a GMP facility 
can follow. Given below is a list of the most common types 
of documents, along with a brief description of each.
1. Quality manual: A global company document that 
describes, in paragraph form, the regulations and/or 
parts of the regulations that the company is required 
to follow. 
2.  Policies: Documents that describe in general terms, and 
not with step-by-step instructions, how specific GMP 
aspects (such as security, documentation, health, and 
responsibilities) will be implemented. 
3. Standard operating procedures (SOPs): Step-by-step 
instructions for performing operational tasks or 
activities. 
4. Batch records: These documents are typically used 
and completed by the manufacturing department. 
Batch records provide step-by-step instructions for 
production-related tasks and activities, besides including 
areas on the batch record itself for documenting such 
tasks.
5.  Test methods: These documents are typically used and 
completed by the quality control (QC) department. 
Test methods provide step-by-step instructions 
for testing supplies, materials, products, and 
other production-related tasks and activities, e.g., 
environmental monitoring of the GMP facility.   
Test methods typically contain forms that have to 
be filled in at the end of the procedure; this is for 
documenting the testing and the results of the testing. 
6.  Specifications: Documents that list the requirements 
that a supply, material, or product must meet before 
being released for use or sale. The QC department will 
compare their test results to specifications to determine 
if they pass the test.
7. Logbooks:  Bound collection of forms used to document 
activities. Typically, logbooks are used for documenting 
the operation, maintenance, and calibration of a piece 
of equipment. Logbooks are also used to record critical 
activities, e.g., monitoring of clean rooms, solution 
preparation, recording of deviation, change controls 
and its corrective action assignment. 
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Hierarchical document system[12]
•  The organization should establish a hierarchical 
document system as mentioned in Figure 1:
•  The regulations that a company is responsible for 
following (e.g., USFDA/EU GMP/ICH/Schedule M, 
etc.) should be at the top of the document pyramid and 
should govern the directives of the sublevels. 
•  The level immediately beneath the regulations, level 1 
documents (e.g., the Quality Manual), should break the 
regulations into parts specific to those that the company 
is required to follow. These documents should establish 
overall principles and guidelines for how the company 
plans on developing, documenting, and implementing a 
cCMP-compliant quality system. Top-level documents 
apply to all departments within a cGMP-compliant 
company and are not specific in nature.
•  The next level, level 2, of documents in the hierarchical 
document pyramid should further break down the parts 
of the regulations into specific subjects or topics. These 
documents (e.g., Company Polices) should establish 
guidelines with which all subordinate level procedures 
must comply to ensure consistency across departments. 
•  Level 2 documents should not provide specific directive 
instructions or forms for documenting data but rather 
provide the overall intentions and guidelines governing 
critical programs or systems as well as explanation for 
the rationale and program designs. These documents 
will apply to all departments within a GMP-compliant 
company. 
•  SOPs should be the next level in the document 
hierarchy after company policy documents. These 
types of documents should provide specific step-
by-step instructions for performing the operational 
tasks or activities that were talked about in the 
previous levels (for example: SOP titled ‘Writing, 
Revising, Numbering, and Distributing Controlled 
Documents’). Level 3 documents (i.e., SOPs)   
should be department specific or function specific.
•  The last level of documents in a document hierarchical 
structure are level 4 documents. These documents 
are the most specific in nature, (e.g., batch record, 
test methods, validation procedures). They apply to a 
specific department, product, equipment, or process. 
Level 4 documents provide step-by-step instructions 
for production-related tasks and activities as well as 
provide a means for documenting such tasks using, 
for example, data sheets, forms, or batch records. 
The details outlined in these documents may override 
directions given in other level documents. (For example: 
the company’s documentation SOP may state that 
numbers be rounded off to three significant figures; 
the batch record, on the other hand, may state that 
all numbers be expressed in scientific notation. Thus, 
instructions in level 4 documents, which are specific 
to a particular process, can overrule the instruction 
mentioned in level 3 documents, which are general in 
nature. The document hierarchy pyramid is one way of 
organizing a company’s documents. 
More/less levels may be added/subtracted to meet the 
company’s specific needs.
HARMONIZED REQUIREMENT
The harmonized requirements were prepared after 
taking into consideration the above mentioned guidance 
documents/regulatory requirements.[4–10]
Site master file
The manufacturer should prepare a succinct document 
in the form of a ‘Site Master File,’ containing specific 
and factual GMP about the production and/or control 
of pharmaceutical manufacturing procedures carried out 
at the premises. It should contain the descriptions of the 
following:
General information: 
•  Brief information on the firm 
•  Pharmaceutical manufacturing activities, as permitted 
by the licensing authority 
•  Other manufacturing activities, if any, carried out on 
the premises 
•  Type of products licensed for manufacture, with 
flowcharts detailing procedure and process flow 
•  Number of employees engaged in the production, 
quality control, storage and distribution 
•  Use of outside scientific, analytical, or other technical 
assistance in relation to manufacture and analysis 
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•  Short description of the quality management system 
of the firm 
•  Products details registered with foreign countries 
Personnel:
•  Organizational chart showing the arrangements for 
quality assurance, including production and quality 
control 
•  Qualification, experience, and responsibilities of key 
personnel
Premises:
•  Simple plan or description of manufacturing areas 
drawn to scale 
•  Nature of construction and fixtures/fittings 
•  Brief description of ventilation systems. More details 
should be given for critical areas with potential risk of 
airborne contamination (schematic drawing of systems). 
Classification of the rooms used for the manufacture 
of sterile products should be mentioned. 
•  Special areas for the handling of highly toxic, hazardous, 
and sensitizing materials. 
•  Brief description of the water system (schematic 
drawings of systems), including sanitation. 
•  Description of planned preventive maintenance 
programs for premises and of the recording system.
Equipment:
•  Brief description of major equipment used in 
production and in the quality control laboratories (a 
list of equipment required) 
•  Description of planned preventive maintenance 
programs for equipment and of the recording system 
•  Qualification and calibration, including the recording 
systems, and arrangements for computerized systems 
validation 
Sanitation:
•  Written specifications and procedures for cleaning 
manufacturing areas and equipment
Documentation:
•  Arrangements for the preparation, revision, and 
distribution of documents 
•  Necessary documentation for the manufacture 
•  Any other documentation related to product quality 
that is not mentioned elsewhere (e.g., regarding 
microbiological control of air and water) 
Production:
•  Brief description of production operations using, 
wherever possible, flow sheets and charts specifying 
important parameters 
•  Arrangements for the handling of starting materials, 
packaging materials, and bulk and finished products; 
this includes the arrangements for sampling, quarantine, 
release, and storage.   
•  Arrangements for the handling of rejected materials 
and products. 
•  Brief description of the general policy for process 
validation. 
Quality control:
•  Description of the quality control system and of the 
activities of the quality control department. Procedures 
for the release of the finished products. 
Loan license manufacture and licensee:
•  Description of the way in which compliance with GMP 
by the loan licensee should be assessed. 
Distribution, complaints, and product recall:
•  Arrangements and recording system for distribution 
•  Arrangements for the handling of complaints and 
product recalls
Self  inspection:
•  Short description of the self-inspection system, 
indicating whether an independent and experienced 
external expert is to be involved in evaluating the 
manufacturer’s compliance with GMP in all aspects of 
production
Export of  drugs
•  Products exported to different countries 
•  Complaints and product recall, if any 
Documentation system and specifications
Documentation is an essential part of the quality assurance 
system and, as such, should be related to all aspects of 
GMP. Its aim is to define the specifications for all materials 
and the method of manufacture and control, to ensure 
that all personnel concerned with manufacture have the 
information necessary to decide whether or not to release 
a batch of a drug for sale, and to provide an audit trail that 
will permit investigation of the history of any suspected 
defective batch. The specifications should describe in detail 
the requirements with which the products or materials used 
or obtained during manufacture have to conform. They 
serve as a basis for quality evaluation.
Manufacturing formulae and processing and packaging 
instructions should specify all the starting materials used 
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and describe all processing and packaging operations. 
Procedures should give directions for performing certain 
operations, e.g., cleaning, clothing, environmental control, 
sampling, testing, and equipment operation. Records should 
provide a history of each batch of product, including its 
distribution, and also of all other relevant circumstances 
pertinent to the quality of the final product.
Written records should be maintained so that data can be 
used for evaluating, at least annually, the quality standards 
of each drug product to determine the need for changes 
in drug product specifications or manufacturing or control 
procedures. Written procedures should be established and 
followed for such evaluations and must include provisions 
for:
•  A review of a representative number of batches, 
whether approved or rejected and, where applicable, 
the records associated with the batch.
•  A review of complaints, recalls, and returned or salvaged 
drug products, and of the investigations conducted.
All documents related to the manufacture of intermediates, 
active pharmaceutical ingredients (API), and finished 
products should be prepared, reviewed, approved, 
and distributed according to written procedures. Such 
documents can be paper-based or in electronic form. 
Documents should be approved, signed, and dated by the 
appropriate responsible persons. No document should be 
changed without authorization and approval.
Each specification for raw materials, intermediates, final 
products, and packing materials should be approved and 
maintained by the quality control department. Periodic 
revisions of the specifications must be carried out 
whenever changes are necessary.
The issuance, revision, superseding, and withdrawal of 
all documents should be controlled, with maintenance 
of revision histories. When a document has been revised, 
systems should be operated to prevent inadvertent use of 
superseded documents. Superseded documents should be 
retained for a specific period of time.
Periodic revisions of the specifications may be necessary to 
comply with new editions of the national pharmacopoeia 
or other official compendia.
Documents should have unambiguous contents: the 
title, nature, and purpose should be clearly stated. They 
should be laid out in an orderly fashion and be easy to 
check. Reproduced documents should be clear and legible. 
The process of reproduction of working documents 
from master documents must not allow any error to be 
introduced through the reproduction process. 
A procedure should be established for retaining all 
appropriate documents (e.g., development history reports, 
scale-up reports, technical transfer reports, process 
validation reports, training records, production records, 
control records, and distribution records). The retention 
periods for these documents should be specified. 
All production, control, and distribution records should be 
retained for at least 1 year after the expiry date of the batch. 
For APIs with retest dates, records should be retained for 
at least 3 years after the batch is completely distributed.
Documents should not be handwritten; however, where 
documents require the entry of data, these entries may 
be made in clear, legible, indelible handwriting. Sufficient 
space should be provided for such entries. Any alteration 
made to the entry on a document should be signed and 
dated; the alteration should permit the reading of the 
original information. Where appropriate, the reason for 
the alteration should be recorded.
During the retention period, originals or copies of records 
should be readily available at the establishment where the 
activities described in such records occurred. Records 
that can be promptly retrieved from another location by 
electronic or other means are acceptable. 
Data may be recorded by electronic data processing systems 
or photographic or other reliable means, but detailed 
procedures relating to the system in use should be available 
and the accuracy of the records should be checked. If 
documentation is handled by electronic data processing 
methods, only authorized persons should be able to enter or 
modify data in the computer, and there should be a record 
of changes and deletions. Access should be restricted by 
passwords or other means and the result of entry of critical 
data should be independently checked. Batch records that are 
electronically stored should be protected by back-up transfer 
onto magnetic tape, microfilm, paper, or other means.
Specifications should be established and documented for 
raw materials, intermediates (where necessary), and API/
formulations, as well as for labeling and packaging materials. 
In addition, specifications may be appropriate for certain 
other materials, such as process aids, gaskets, or other 
materials used during the production of intermediates or 
API/formulations that could critically impact on quality. 
Acceptance criteria should be established and documented 
for in-process controls. 
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If electronic signatures are used on documents, they should 
be authenticated and secure. 
Equipment cleaning and use record
Records of major equipment use, cleaning, sanitization 
and/or sterilization, and maintenance should show the 
date, time (if appropriate), product, and batch number of 
each batch processed in the equipment and the name and 
signature of the person who has performed the cleaning 
and maintenance. The persons performing and double-
checking the cleaning and maintenance should date and sign 
or initial the log, indicating that the work was performed. 
Entries in the log should be in chronological order.
Cross-contamination should be avoided by appropriate 
technical or organizational measures, for example:
•  Production in segregated areas (required for products 
such as the penicillins, live vaccines, live bacterial 
preparations, and some other biologicals), or by 
campaign (separation in time) followed by appropriate 
cleaning
•  Providing appropriate air-locks and air extraction
•  Minimizing the risk of contamination caused by 
recirculation or re-entry of untreated or insufficiently 
treated air
•  Keeping protective clothing inside areas where products 
with special risk of cross-contamination are processed
•  Using cleaning and decontamination procedures 
of known effectiveness, as ineffective cleaning of 
equipment is a common source of cross-contamination
•  Using ‘closed systems’ of production 
•  Testing for residues and use of cleaning status labels 
on equipment 
If equipment is dedicated to manufacturing one intermediate 
or API, then individual equipment records of different 
activities like cleaning, maintenance, batch log, etc., are 
not necessary, provided the batch record has complete 
traceability of this information. In case of formulation 
manufacturing, the appropriate cleaning procedure should 
be established to ensure removal of any residue of the 
previous product.
Records of raw materials, intermediates, labeling, and 
packaging materials
Records should be maintained, including: 
•  The name of the manufacturer; identity and quantity 
of each shipment of each batch of raw materials, 
intermediates, or labeling and packaging materials; the 
name of the supplier; the supplier’s control number(s) 
(if known) or other identification number; the number 
allocated on receipt; and the date of receipt; 
•  The results of any test or examination performed and 
the conclusions derived from this; 
•  Records tracing the use of materials;
•  Documentation of the examination and review of 
labeling and packaging materials for conformity with 
established specifications; 
•  The final decision regarding rejected raw materials, 
intermediates, or labeling and packaging materials.
Starting materials in the storage area should be appropriately 
labeled. Labels should bear at least the following 
information:
•  The designated name of the product and the internal 
code reference, where applicable
•  The batch number given by the supplier and, on 
receipt, the control or batch number (if any) given by 
the manufacturer; these must be documented so as to 
ensure traceability
•  The status of the contents (e.g., on quarantine, on test, 
released, rejected, returned, recalled, etc.)
•  Where appropriate, an expiry date or a date beyond 
which retesting is necessary
Master (approved) labels should be maintained for 
comparison with issued labels. 
Master production instructions/master production 
and control records (MPCR)/master formula card 
(MFC)
To ensure uniformity from batch to batch, master 
production instructions for each intermediate or API/
finished product should be prepared, dated, and signed by 
one person and independently checked, dated, and signed 
by a second person in the quality unit(s). 
Competent persons experienced in production and 
quality control should be responsible for the content and 
distribution within the firm of instructions and master 
formulae. These should be duly signed and dated.
Outdated master formulae should be withdrawn but 
retained for reference. Copies of the master formula should 
be prepared in a manner that will eliminate any possibility 
of transcription error.
In certain circumstances, for example, in the first 
production runs following pilot development, the master 
formula might need to be amended. Any amendments must 
be formally authorized and signed by competent person(s). 
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The amended document should be replaced at the earliest 
opportunity by a newly prepared master formula.
Processing should be carried out in accordance with the 
master formula. Master production instructions should 
include: 
•  The name of the intermediate/API/formulation being 
manufactured and an identifying document reference 
code, if applicable 
•  A complete list of raw materials and intermediates 
(designated by names or codes sufficiently specific to 
identify any special quality characteristics) 
•  An accurate statement of the quantity or ratio of each 
raw material or intermediate to be used, including the 
unit of measure. Where the quantity is not fixed, the 
calculation for each batch size or rate of production 
should be included. Variations to quantities should be 
included wherever justified 
•  The production location and major production 
equipment to be used 
•  Detailed production instructions, including the: 
□  Sequences to be followed 
□  Ranges of process parameters to be used
□  The methods, or reference to the methods, to be 
used for preparing the critical equipment (e.g., 
cleaning, assembling)
□  Sampling instructions and in-process controls, with 
their acceptance criteria, where appropriate 
□  Time limits for completion of individual processing 
steps and/or the total process, where appropriate 
□  Expected yield ranges at appropriate phases of 
processing or time. 
•  Where appropriate, special notations and precautions 
to be followed, or cross-references to these 
•  Instructions for storage of the intermediate or API/
semi-finished formulations to assure its suitability for 
use; instructions should cover the labeling (specimen 
labels and packaging materials and special storage 
conditions with time limits, where appropriate).
Batch production records/batch production and 
control records (BPCR)/batch manufacturing record 
(BMR)
Batch production records should be prepared for each 
intermediate and API/formulation and should include 
complete information relating to the production and 
control of each batch. The batch production record 
should be checked before issuance to assure that it is the 
correct version and a legible accurate reproduction of the 
appropriate master production instruction. If the batch 
production record is produced from a separate part of 
the master document, that document should include a 
reference to the current master production instruction 
being used. 
Before any processing begins, a check should be performed 
and recorded to ensure that the equipment and workstation 
are clear of previous products, documents, or materials not 
required for the planned process and that the equipment 
is clean and suitable for use. 
These records should be numbered with a unique batch or 
identification number and dated and signed when issued. 
In continuous production, the product code together with 
the date and time can serve as the unique identifier until 
the final number is allocated. 
The batch number should be immediately recorded in 
a logbook or by electronic data processing system. The 
record should include date of allocation, product identity, 
and size of batch.
Documentation of completion of each significant step in 
the batch production records (batch production and control 
records) should include: 
•  Dates and, when appropriate, times
•  Identity of major equipment used (e.g., reactors, driers, 
mills, etc.) 
•  Specific identification of each batch, including weights, 
measures, and batch numbers of raw materials, 
intermediates, or any reprocessed materials used during 
manufacturing 
•  Actual results recorded for critical process parameters 
•  Any sampling performed 
•  Signatures of the persons performing and directly 
supervising or checking each critical step in the 
operation 
•  In-process and laboratory test results 
•  Actual yield at appropriate phases or times 
•  Description of packaging and label 
•  Representative label (commercial supply) 
•  Any deviation noted, its evaluation, and investigation 
conducted (if appropriate) or reference to that 
investigation (if stored separately) 
•  Results of release testing 
•  All analytical records relating to the batch, or a reference 
that will permit their retrieval
•  A decision for the release or rejection of the batch, 
with the date and signature of the person responsible 
for the decision
•  The production record review
Production and quality control records should be reviewed 
as part of the approval process of batch release. Any 
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divergence or failure of a batch to meet its specifications 
should be thoroughly investigated. The investigation 
should, if necessary, extend to other batches of the same 
product and other products that may have been associated 
with the specific failure or discrepancy. A written record 
of the investigation should be made and should include 
the conclusion and follow-up action. 
The following information should be recorded at the time 
each action is taken (the date must be noted and the person 
responsible should be clearly identified by signature or 
electronic password):
•  The name of the product, the batch number and the 
quantity of product to be packed, as well as the quantity 
actually obtained and its reconciliation
•  The date(s) and time(s) of the packaging operations
•  The name of the responsible person carrying out the 
packaging operation
•  The initials of the operators of the different significant 
steps
•  The checks made for identity and conformity with 
the packaging instructions, including the results of in-
process controls
•  Details of the packaging operations carried out, 
including references to equipment and the packaging 
lines used and, when necessary,   instructions for 
keeping the product unpacked or a record of returning 
product that has not been packaged to the storage area 
•  Whenever possible, the regular check for correctness 
of printing (e.g. batch number, expiry date and other 
additional overprinting) and specimen samples collected 
•  Notes on any special problems, including details of any 
deviation from the packaging instructions, with written 
authorization by an appropriate person
•  The quantities and reference number or identification 
of all printed packaging materials and bulk product 
issued, used, destroyed, or returned to stock and the 
quantities of product obtained; this is necessary to 
permit an adequate reconciliation.
Laboratory control records 
Laboratory control records should include complete data 
derived from all tests conducted to ensure compliance 
with established specifications and standards, including 
examinations and assays, as follows: 
•  A description of samples received for testing, including 
the material name or source, batch number and, 
where appropriate, the manufacturer and/or supplier; 
alternatively, other distinctive code, date of sample 
taken and, where appropriate, the quantity of the sample 
and date the sample was received for testing
•  A statement of, or reference to, each test method used 
•  A statement of the weight or measure of sample used 
for each test as described by the method; data on, 
or cross-reference to, the preparation and testing of 
reference standards, reagents, and standard solutions 
•  A complete record of all raw data generated during 
each test, in addition to graphs, charts, and spectra from 
laboratory instrumentation, all properly identified to 
show the specific material and the batch tested 
•  A record of all calculations performed in connection 
with the test including, for example, units of measure, 
conversion factors, and equivalency factors 
•  A statement of the test results and how they compare 
with established acceptance criteria 
•  The signature of the person who performed each test 
and the date(s) on which the tests were performed 
•  The date and signature of a second person, showing 
that the original records were reviewed for accuracy, 
completeness, and compliance with established standards.
Complete records should also be maintained for: 
•  Any modifications to an established analytical method 
•  Periodic calibration of laboratory instruments, 
apparatus, gauges, and recording devices 
•  All stability testing performed on APIs/formulations 
•  Out-of-specification (OOS) investigations 
Complete records should be maintained of any testing and 
standardization of laboratory reference standards, reagents, 
and standard solutions; record should also be maintained of 
periodic calibration of laboratory instruments, apparatus, 
gauges, and recording devices.
Batch production record review
Written procedures should be established and followed 
for the review and approval of batch production and 
laboratory control records, including packaging and 
labeling, to determine compliance of the intermediate 
or API with established specifications before a batch is 
released or distributed. 
Batch production and laboratory control records of critical 
process steps should be reviewed and approved by the 
quality unit(s) before an API batch is released or distributed. 
Production and laboratory control records of non-critical 
process steps can be reviewed by qualified production 
personnel or other units, following procedures approved 
by the quality unit(s). 
All deviation, investigation, and OOS reports should be 
reviewed as part of the batch record review before the 
batch is released. 
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The quality unit(s) can delegate to the production unit the 
responsibility and authority for release of intermediates, 
except for those shipped outside the control of the 
manufacturing company. 
Distribution record should be maintained and must include 
the batch number; quantity produced; name, address, and 
contact details of customer; quantity supplied; and date 
of supply.
POLICY FOR IMPLEMENTATION
The following approach pertaining to ‘documentation and 
records’ may be helpful for pharmaceutical manufacturers 
to meet the expectations of different regulatory agencies. 
Write good procedures and follow them[11]
Think about what happens in a workplace if written 
procedures are not available. People rely on more senior 
employees to tell them how to do things and then do their 
job from memory. This is fine for a company making 
garden pots, but not so good when the products being 
made are pharmaceuticals and can even cause death! 
In the food, drug, and medical device industry it is critical 
that good procedures are in place to ensure a controlled 
and consistent performance; it is an essential part of GMP. 
Procedures should be clear, concise, and logical. Consider 
hiring a professional technical writer to do the job. Unlike 
permanent employees, they know how write well and will 
perform usability tests to ensure that the documents work. 
Review of procedure by an independent party can also help 
to improve process. 
Outline the task before you begin writing the procedure. 
Create a brief breakdown of the important steps and 
key points related to the task; a flowchart is a useful tool. 
Remember that people do not usually read procedures 
from start to finish; they tend to scan the document for 
key words. To make information easier to digest and follow, 
break the procedure into chunks and use the following:
•  Headings
•  Tables
•  Bullet points
•  Diagrams
When writing out any procedure, one should try and 
visualize the person who will be following that procedure. 
Use language that that person can understand. Do not 
include too much or too little information. Increase the 
readability of the instructions by using simple sentences 
and by writing in a conversational style. Most companies 
have a 3-year review cycle for their documents; however, 
this can be set according to the likelihood of change in the 
process that the document relates to.
Following procedures[11]
It is all very well to have great written procedures in place 
but to ensure a controlled and consistent performance they 
need to be followed; it is a GMP requirement. Frequently, 
the steps described in a written procedure may not appear 
to be the most efficient way of working. Taking shortcuts 
may save time or make the task easier, but one should never 
deviate from a written procedure without the approval of 
a supervisor or the quality department.
There are two main reasons for this:
•  Many shortcuts may create pitfalls that can be costly in 
the end.
•  Each step in a procedure has been included for a 
purpose.
Even though the rationale of a particular step may not 
be immediately apparent, it may have been put there 
as a check for another stage of the process. Ideas for 
improvement should always be encouraged, but do not 
change procedures without assessing the impact on the 
entire process.
Keep good records[11]
Good records enable one to track all activities performed 
during batch manufacture, from the receipt of raw materials 
to the final product release; they provide a history of the 
batch and its distribution. It is an essential part of GMP 
to keep accurate records, and during an audit it helps 
convey the message that procedures are being followed. 
It also demonstrates that the processes are known and are 
under control.
Remember!!!
•  Record all necessary information immediately upon 
completion of a task
•  Never trust your memory or write results on loose 
pieces of paper
•  Write your name legibly in ink. Remember that by 
signing records you are certifying that the record is 
correct and that you have performed the task as per 
the defined procedure.
•  Draw a single line through any mistakes, and initial and 
date the correction. Include a reason for the correction 
at the bottom of the page.
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•  Record details if you deviate from a procedure. Ask 
your supervisor or the quality department for advice 
if a deviation should occur.
•  Do not document someone else’s work unless you are 
designated and trained to do so.
•  Never assume that undocumented work has been 
properly completed – if it’s not written down, then it 
didn’t happen!
Documents/SOPs required
The following documents and procedures should be 
prepared to fulfill the above mentioned requirements. 
The data generated through these procedures should be 
maintained to show compliance with the above mentioned 
requirements.
•  Prepare apex documents like Quality Policy, Quality 
Manual, Site Master File, Validation Master Plan, etc. to 
describe the quality commitments of the management
•  Define the roles and responsibilities of all personnel 
working in the organization
•  Prepare policy for periodic review of documents. 
Ensure that the current industrial practices and 
pharmacopoeial requirements are fulfilled by the current 
versions of documents
•  SOP for document (SOPs, MPCR, BPCR, validation/
qualification protocols, formats) preparation, review, 
approval, training, distribution, control, and its retention 
•  Procedure for maintaining revision history
•  Management, control, and retention of superseded or 
obsolete documents
•  Document archival and retrieval procedure
•  Handling, archival, retrieval, and retention of electronic 
records/documents
•  Procedure for control of electronic signatures
•  Equipment cleaning and sanitation procedure
•  Issuance and control of equipment logs
•  Document describing measures taken for avoidance of 
cross-contamination and its training records
•  Cleaning validation master plan
•  Procedure for batch-to-batch and product-to-product 
cleaning and its verification to ensure removal of residue 
of previous batch/product
•  Records for incoming raw materials and packaging 
materials
•  SOP for preparation of process validation protocol and 
reports
•  SOP for preparation of master production control 
records
•  SOP for preparation of batch manufacturing and 
control records
•  SOP for allocation of batch number
•  Calibration master plan and calibration reports
•  Batch release procedure 
•  SOP for preparation and control of QC data sheet
•  SOP for allocation of analytical control number 
•  Procedure for review of analytical data
•  SOP for investigation of OOS results
•  SOP for change control, revision of any process or 
documents, or upgradation of facility or equipment 
should be routed through impact assessment and 
change control procedure
•  SOP for deviation handling system 
•  SOP for corrective and preventive action (CAPA)
•  SOP for stability testing
•  SOP for product distribution and its control
CHECKLIST FOR COMPLIANCE ASSESSMENT
The following checkpoints/checklist may help to assess the compliance of ‘documentation and records’ with GMP 
requirements 
Checklist/checkpoints Document to refer Y/N/NA Remarks
•  Is there an SOP for writing, handling, and updating SOPs?  SOP for SOP
•  Are all documents passing through appropriate review and approval procedure? Template of all document
•  Distribution records maintained for all documents? Traceability of any specification/SOP
•  Is there any procedure for ensuring that the current version of the documents are 
being used?
Document distribution and retrieval 
record
•  Is responsibility assigned for issuance and control of documents? Job description
•  Is history of changes made in documents maintained? Document history record
•  Does document control procedure include the procedure for handling obsolete 
versions?
Traceability of compliance
•  Does the storage/archival of documents provide a suitable environment to minimize 
deterioration or damage to quality-related documents?
Archive 
•  Is there a system for periodic review of documents? Document review/revision SOP
•  Is there a document control system available? Respective SOP
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Checklist/checkpoints Document to refer Y/N/NA Remarks
•  Are all quality-related documents being retained for history? Superseded/obsolete document
•  Are corrections made in documents signed and explained? Does the SOP reflect 
this policy?
SOP for correction of entries
•  Are electronic signatures used? If yes, is there an adequate control or security 
measure?
SOP
•  Is equipment cleaning being recorded in the logbook?  Logbook
•  Is preventive maintenance activity being recorded in the logbook? Or is there any 
other appropriate documentation?
Preventive maintenance plan and 
logbook
•  Is RM available at the warehouse, labeled with the following details:
-  Lot No.
-  Receipt date
-  Approval/status label
In RM store
•  Are master labels retained?
  (For all lots that are packed and supplied, master labels should be part of Batch 
Packaging Record (BPR) or be separately filed)
BPR / BPCR
•  Does the MPCR/MFC mention the following details?
-  Name of material, with code
- Quantity
- Rationale
-  Equipment to be used
-  Process parameter
-  In-process checks
-  Sampling instruction
-  Expected yield
MPCR/MFC
•  Have process parameters critical to quality been defined and, if parameters are 
exceeded, is the affect on quality known?
MPCR and development report
•  Is there a system for identifying major equipment, instruments, and production 
lines? Is this information included in batch production and control records where 
appropriate?
MPCR and BPCR
•  Is there a system to determine customer requirements related to the product and 
supply of the product?
Policy and evident document
•  Is there a formal procedure to communicate the agreed upon customer requirements 
to the appropriate personnel?
SOP and evident document
•  Is there a procedure in place to assure that the manufacturer and the customer have 
mutually agreed upon the specifications and other requirements? If not, what is the 
alternative process?
Agreement
•  Is there a system to assure that any mutually agreed customer-initiated changes are 
promptly incorporated?
Agreement
•  Is there an adequate system in place to assure that significant process changes, 
including the use of subcontractors and their effect on the product, are 
communicated to the customer?
Agreement
•  Does the batch record mention  the following:
-  Deviations, if any
-  In-process results
-  Release statement
-  All details should match with MPCR
BPCR
•  Are specifications for all material available with QC and user department? Traceability at QC
•  Is method of analysis available with QC? Traceability at QC
•  Is there an SOP for investigation of OOS? SOP and evident document
•  Does the analytical report/COA mention the reference of STP used? Analytical report
•  Is analysis being performed by qualified personnel? Analyst and its qualification and 
copy of FDA approval 
•  Are batch record and analytical records being reviewed by QA before dispatch? SOP on batch release
GMP: Good manufacturing practice, cGMP: Current good manufacturing practice, SOP: Standard operating procedures, QC: Quality control, MFC: Master formula card, 
MPCR: Master production and control records, BMR: Batch manufacturing record, BPR: Batch packaging record, BPCR: Batch production and control records, API: Active 
pharmaceutical ingredients, OOS: Out-of-specification, RM: Raw material, COA: Certificate of analysis, STP: Standard test procedure, QA: Quality assurance
CONCLUSION
Pharmaceutical manufacture and regulation is clearly an 
international business. With the increasing emphasis on 
harmonization efforts and standard setting, as well as mutual 
recognition agreements, knowledge of foreign regulations 
is a must both for understanding the future direction of 
these efforts as well as for international supply of drug 
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products. It is anticipated that the approach described 
here will be a useful reference work for those personnel 
preparing and using documents for pharmaceutical 
manufacture. It can serve as a tool for training staff and 
may prove to be useful for quality assurance professionals 
for assessment of compliance during self-inspection. It is 
again emphasized that documentation is a very important 
aspect of GMP and will enhance the visibility of the quality 
assurance function. 
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